ALEXANDRIA, Va., June 12 -- United States Patent no. 12,298,311, issued on May 13, was assigned to Saitama Medical University (Saitama, Japan).
"Immunological biomarker for predicting clinical effect of cancer" was invented by Hiroshi Kagamu (Saitama, Japan).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the prediction of responsiveness to cancer immunotherapy of a subject based on the T-cell composition of the subject, and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining responsiveness to cancer immunotherapy of a subject. Responsiveness to cancer immunotherapy is predicted by de...